Seer, Inc. (SEER) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Seer, Inc. (SEER:NASDAQ), powered by AI.

Current Price
$1.70
P/E Ratio
-1.2
Market Cap
106M
Sector
Healthcare
What is the Seer, Inc. stock price forecast?

Seer, Inc. is currently trading at $1.70. View real-time AI analysis on Alpha Lenz.

What is Seer, Inc. insider trading activity?

View the latest insider trading data for Seer, Inc. on Alpha Lenz.

What is Seer, Inc.'s P/E ratio?

Seer, Inc.'s P/E ratio is -1.2.

Seer, Inc.

$1.70
NASDAQSEER
Ask about Seer, Inc.'s future dividend policy...
Alpha Chat Insight

Seer, Inc. trades at a P/E of -1.2 (undervalued) with modest ROE of -23.9%. 3Y revenue CAGR of 29.7% highlights clear growth momentum.

Ask for details

Company Overview

Seer Inc. operates as a biotechnology company renowned for its expertise in developing innovative solutions for protein analysis. The core purpose of Seer is to advance scientific understanding by providing high-throughput and scalable tools to decode the proteome—the entire complement of proteins expressed by a cell, tissue, or organism. Seer’s Proteograph Product Suite significantly enhances biological research by enabling a detailed examination of protein dynamics, aiding in the development of personalized medicine and fostering breakthroughs in disease diagnostics and therapy. This cutting-edge technology is pivotal in the healthcare and pharmaceuticals sectors, where understanding proteomic profiles can lead to improved therapeutic outcomes and clinical insights. Founded to bridge the gap between genomics and proteomics, Seer Inc. plays a critical role in empowering researchers and clinicians to uncover new biomolecular insights, thereby expanding the capabilities of precision medicine. The company's contributions to the life sciences market are not only significant for scientific advancement but also for the commercialization of research into practical healthcare applications.

CEODr. Omid C. Farokhzad M.D., Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees134

Company Statistics

(FY 2024)

Profile

Market Cap$105.99M
Revenue$13.95M
Shares Out0.00
Employees134

Margins

Gross48.99%
EBITDA-673.44%
Operating-717.72%
Pre-Tax-620.21%
Net-620.91%

Valuation

P/E-1.22
P/B0.32
EV/Sales7.60
EV/EBITDA-0.97
P/FCF-2.13

Growth (CAGR)

Rev 3Yr29.69%
Rev 5Yr199.37%
Op Inc 3YrN/A
Op Inc 5YrN/A
Net Inc 3YrN/A
Net Inc 5YrN/A

Returns

ROA-21.57%
ROE-23.91%
ROIC-24.94%

Financial Health

Cash & Cash Equivalents$40.75M
Net Debt$-1.73M
Debt/Equity11.91%
Interest CovN/A
Ask Alpha Chat

Frequently Asked Questions

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
Seer, Inc. (Healthcare) Stock Forecast & Analysis $1.70 | Alpha Lenz